Tarsus Pharmaceuticals, Inc. announced the appointment of Jeff Farrow as the Company's Chief Strategy Officer, effective as of April 24, 2023. The Company's Board of Directors approved the Transition and appointment of Mr. Farrow on April 18, 2023. Mr. Farrow, 61, has served as a board member of Clover Biotherapeutics since September 2021.

Mr. Farrow previously served as the chief financial officer of Global Blood Therapeutics, Inc., a biopharmaceutical company, from April 2016 to December 2022 when it as acquired by Pfizer. At Global Blood Therapeutics, Inc., he was part of the team responsible for the successful regulatory approval and commercial launch of Oxbryta for the treatment of sickle cell disease. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015.

Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG.

Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).